Nature Medicine, Published online: 27 May 2025; doi:10.1038/s41591-025-03704-9
In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized phase 2 TheraP trial, low ctDNA levels at baseline were predictive of clinical benefit from [177Lu]Lu–PSMA-617, and PTEN or ATM alterations were identified as potential biomarkers of response.
